BTAI has been the subject of a number of other reports. SunTrust Banks began coverage on BioXcel Therapeutics in a report on Tuesday, November 12th. They set a “buy” rating and a $24.00 price objective for the company. HC Wainwright set a $25.00 price objective on BioXcel Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 21st. Zacks Investment Research raised BioXcel Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, September 11th. Finally, BMO Capital Markets set a $21.00 price objective on BioXcel Therapeutics and gave the company a “buy” rating in a report on Wednesday, September 18th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. BioXcel Therapeutics presently has an average rating of “Buy” and an average target price of $20.60.
Shares of BTAI stock opened at $6.25 on Tuesday. The stock has a market cap of $92.88 million, a P/E ratio of -4.73 and a beta of 2.80. BioXcel Therapeutics has a one year low of $2.41 and a one year high of $12.00. The stock has a fifty day moving average price of $5.27 and a 200 day moving average price of $9.02. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.04 and a quick ratio of 5.04.
BioXcel Therapeutics (NASDAQ:BTAI) last issued its quarterly earnings data on Thursday, November 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.59) by $0.02. Equities research analysts anticipate that BioXcel Therapeutics will post -2.28 EPS for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the business. Capital Investment Advisory Services LLC bought a new position in shares of BioXcel Therapeutics during the second quarter valued at $53,000. Rational Advisors LLC acquired a new stake in shares of BioXcel Therapeutics in the third quarter valued at $48,000. Strs Ohio increased its stake in shares of BioXcel Therapeutics by 431.3% in the third quarter. Strs Ohio now owns 8,500 shares of the company’s stock valued at $59,000 after buying an additional 6,900 shares in the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in shares of BioXcel Therapeutics in the second quarter valued at $138,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of BioXcel Therapeutics in the second quarter valued at $198,000. 20.66% of the stock is owned by institutional investors.
BioXcel Therapeutics Company Profile
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.
Featured Story: How to invest using market indexes
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.